Engineered immune cells take on rare sarcomas in new trial
Disease control
Completed
This phase 2 trial tests a treatment called Lete-Cel, which uses a patient's own immune cells that have been specially trained to attack cancer cells. It is for people with advanced synovial sarcoma or myxoid/round cell liposarcoma whose tumors have a specific marker (NY-ESO-1) a…
Phase: PHASE2 • Sponsor: USWM CT, LLC • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC